Literature DB >> 10463269

Cyclopamine-induced holoprosencephaly and associated craniofacial malformations in the golden hamster: anatomic and molecular events.

S Coventry1, R P Kapur, J R Siebert.   

Abstract

Holoprosencephaly is a complex congenital malformation of the brain and is often associated with a spectrum of facial anomalies ranging from normocephaly or nondiagnostic changes to cleft lip/palate (premaxillary dysgenesis), cebocephaly, ethmocephaly, and cyclopia. The primary insult is thought to occur during gastrulation, when prechordal mesenchyme and overlying anterior neural plate undergo complex developmental interactions. Exposure to cyclopamine, a steroid isolated from the desert plant Veratrum californicum, causes holoprosencephaly in mammalian embryos. We have begun to study the pathogenesis of cyclopamine-induced holoprosencephaly and associated craniofacial anomalies in Syrian golden hamsters (Mesocricetus auratus). Embryos were exposed to a single maternal dose of cyclopamine during gastrulation on embryonic day (E) 7.0. By E13.0, 62% of fetuses showed craniofacial malformations, including premaxillary dysgenesis, ocular hypotelorism, and cebocephaly. Facial anomalies were associated with absence of the premaxilla and abnormalities of the midline cranial base, particularly the ethmoid and sphenoid bones. Histological sections from cyclopamine-treated embryos at earlier stages showed marked deficiency of cranial mesenchyme derived from the rostral neural crest. Expression of two transcription factors, HNF-3 beta and Hox-b5, which have been implicated in specification of rostral and caudal neural crest cells, respectively, were examined immunohistochemically. Treatment with cyclopamine caused a transient loss of HNF-3 beta immunoreactivity in prechordal mesenchyme, but had no effect on Hox-b5 expression. The findings suggest that an early event in the pathogenesis of cyclopamine-induced holoprosencephaly may be altered expression of selected proteins in the prechordal mesenchyme and floor plate with secondary impaired development of the adjacent neural plate and cranial neural crest.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10463269     DOI: 10.1007/s100249900004

Source DB:  PubMed          Journal:  Pediatr Dev Pathol        ISSN: 1093-5266


  8 in total

1.  Signaling by SHH rescues facial defects following blockade in the brain.

Authors:  H Jonathan Chong; Nathan M Young; Diane Hu; Juhee Jeong; Andrew P McMahon; Benedikt Hallgrimsson; Ralph S Marcucio
Journal:  Dev Dyn       Date:  2012-02       Impact factor: 3.780

2.  Identification of Hedgehog signaling inhibitors with relevant human exposure by small molecule screening.

Authors:  Robert J Lipinski; Wade Bushman
Journal:  Toxicol In Vitro       Date:  2010-04-29       Impact factor: 3.500

3.  Cleft lip and palate results from Hedgehog signaling antagonism in the mouse: Phenotypic characterization and clinical implications.

Authors:  Robert J Lipinski; Chihwa Song; Kathleen K Sulik; Joshua L Everson; Jerry J Gipp; Dong Yan; Wade Bushman; Ian J Rowland
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2010-04

4.  Temporal perturbations in sonic hedgehog signaling elicit the spectrum of holoprosencephaly phenotypes.

Authors:  Dwight Cordero; Ralph Marcucio; Diane Hu; William Gaffield; Minal Tapadia; Jill A Helms
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

5.  Signaling by bone morphogenetic proteins directs formation of an ectodermal signaling center that regulates craniofacial development.

Authors:  Silvia Foppiano; Diane Hu; Ralph S Marcucio
Journal:  Dev Biol       Date:  2007-09-20       Impact factor: 3.582

6.  Ipriflavone attenuates the degeneration of cartilage by blocking the Indian hedgehog pathway.

Authors:  Li Guo; Xiaochun Wei; Zhiwei Zhang; Xiaojian Wang; Chunli Wang; Pengcui Li; Chunfang Wang; Lei Wei
Journal:  Arthritis Res Ther       Date:  2019-05-02       Impact factor: 5.156

7.  Disrupting the Indian hedgehog signaling pathway in vivo attenuates surgically induced osteoarthritis progression in Col2a1-CreERT2; Ihhfl/fl mice.

Authors:  Jingming Zhou; Qian Chen; Beate Lanske; Braden C Fleming; Richard Terek; Xiaochun Wei; Ge Zhang; Shaowei Wang; Kai Li; Lei Wei
Journal:  Arthritis Res Ther       Date:  2014-01-15       Impact factor: 5.156

8.  A novel therapeutic strategy for cartilage diseases based on lipid nanoparticle-RNAi delivery system.

Authors:  Shaowei Wang; Xiaochun Wei; Xiaojuan Sun; Chongwei Chen; Jingming Zhou; Ge Zhang; Heng Wu; Baosheng Guo; Lei Wei
Journal:  Int J Nanomedicine       Date:  2018-01-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.